Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Status Completed

Clinical Trial Summary

This large randomized trial tested whether phenobarbital given to a pregnant woman about to deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to 32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were randomized to phenobarbital or usual care. They were treated until they deliver or the fetus reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos corrected age for neurodevelopmental outcome.

Clinical Trial Description

The administration of phenobarbital to pregnant women before delivery has been thought to decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this potential neuroprotective therapy further, we determined the effect of antenatal administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and early death. Women who were 24 to 33 weeks pregnant and who were expected to deliver their infants within 24 hours were randomly assigned to receive either intravenous phenobarbital (10 mg/kg body weight) or placebo, followed by maintenance doses until delivery or 34 wks gestation. Infants less than 34 wks at birth underwent serial cranial ultrasonography to detect the presence of intracranial hemorrhage. The sample size of 1038 pregnancies was based on an intracranial hemorrhage rate of 20 percent in the placebo and less than 12 percent in the phenobarbital group; 90 percent power; a 5 percent two-tailed type 1 error; and an 8 percent noncompliance rate. The twin with the highest grade of intracranial hemorrhage was included.

Degree of maternal sedation was evaluated after administration of study drug. Neonatal ultrasound exams were performed at 3-5 days, 10-14 days, and 38-42 wks postmenstrual age; neonatal medications were recorded during the first week of life; treatments, and outcomes were recorded through death, discharge, or 120 days, whichever occurred first. Neurodevelopmental outcome was evaluated at 18-22 months corrected age by certified examiners masked to treatment status. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00009620
Study type	Interventional
Source	NICHD Neonatal Research Network
Contact
Status	Completed
Phase	Phase 3
Start date	February 1993
Completion date	February 1997

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03146351` - The Effects of Family Centered Intervention Program on Preterm Infants	N/A
Completed	`NCT02064712` - Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates	N/A
Completed	`NCT00365703` - Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best?	N/A
Terminated	`NCT00179933` - The Impact of Implementing NIDCAP on Preterm Infants in the NICU	N/A
Completed	`NCT00114543` - Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight	Phase 3
Terminated	`NCT05030012` - Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants	N/A
Completed	`NCT00552383` - The Edmonton Randomised Controlled Trial of NIDCAP - Based Developmental Care	N/A
Completed	`NCT00011362` - Dexamethasone Therapy in VLBW Infants at Risk of CLD	Phase 3
Completed	`NCT06308471` - Effect of Baby Massage on Oral Motor Skills of Premature Babies	N/A
Completed	`NCT01863043` - Aspiration of Residual Gastric Contents	N/A
Completed	`NCT05462509` - Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda	N/A
Not yet recruiting	`NCT06109350` - The Effect of Physical Therapy Intervention on Motor Performance in Bhutanese Preterm Infants	N/A
Completed	`NCT03551600` - Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Terminated	`NCT02599545` - Testosterone and Cortisol Levels in Infants
Completed	`NCT02611284` - Less Invasive Beractant Administration in Preterm Infants	N/A
Completed	`NCT01193270` - Vitamin E for Extremely Preterm Infants	Phase 1
Completed	`NCT00455169` - Influenza Vaccine in Premature Infants	Phase 4
Withdrawn	`NCT00536445` - Use of NAVA in Intubated Preterm	Phase 1/Phase 2
Completed	`NCT00579553` - Comparing IM vs. Vaginal Progesterone for Pre-term Birth	N/A
Completed	`NCT01203423` - Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage — Phenobarbital

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms